A Agilent Technologies Inc.

Agilent Technologies Launches New Research-Grade Triple Quadrupole LC/MS System

Agilent Technologies Inc. (NYSE: A) today expanded its portfolio of scientific instruments with a new LC/MS system that provides even greater sensitivity and accuracy for applications such as peptide quantitation, food safety, environmental testing, clinical research and forensic toxicology.

The new Agilent 6495B Triple Quadrupole LC/MS System combines high-performance liquid chromatography (HPLC) and triple quadrupole mass spectrometry in an integrated system that delivers outstanding operational efficiencies.

Built on the success of the 6495A Triple Quadrupole LC/MS System, the 6495B provides improved mass range, scan speed and polarity switching – all of which enable scientists to better analyze molecules from a wide array of sample matrices.

The 6495B also incorporates a new gate valve that facilitates even quicker and easier removal of the inlet capillary without having to vent the instrument, enabling increased uptime and productivity. This new gate valve can withstand thousands of opening and closing cycles without losing its tight vacuum seal. With fewer moving components, it also minimizes wear and particulate generation, reducing the need for maintenance.

Coupled with Agilent MassHunter software, which simplifies sample management and analysis, the Agilent 6495B Triple Quadrupole LC/MS System accelerates analysis, delivering even more reliable results and quickly turning data into insights.

“Laboratories demand instruments that provide quick and reliable answers to their analytical problems,” said Monty Benefiel, Agilent vice president and general manager of the company's Mass Spectrometry Division. “From low-level quantification of peptides in life science research, to the detection of mycotoxins and other contaminants in food, the Agilent 6495B is an excellent choice.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
08/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch